The 2010 Government Supported Benefits 'Virtual' Summit
A unique web-based conference and series of accredited on-line self-learning programs focused on the impact of Heathcare reform on providers and patient care.
|
The 2010 Government Supported Benefits 'Virtual' Summit |
A unique web-based conference and series of accredited on-line self-learning programs focused on the impact of Heathcare reform on providers and patient care. |
|
Current Trends in Management of Blood Glucose in Type 2 Diabetes Mellitus
Needs Assessment:
Type 2 diabetes mellitus, the sixth leading cause of death in the U.S., is directly responsible for more then 73,000 deaths annually and is a contributing factor in more than 220,000 deaths. More than 20 million Americans have diabetes of which 6 million are undiagnosed. It is the leading cause of kidney failure and blindness in adults. Evidence-based guidelines for the management of Type 2 diabetes focus on three areas: lifestyle changes (that include diet, exercise and weight loss); management of cardiovascular disease risk factors (including hypertension, dyslipidemia and microalbuminuria with the use of aspirin, statins and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers); and management of blood glucose levels with pharmacotherapy.
The Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes identified metformin, insulin and sulfonylureas as first-tier agents and GLP-1 agonist (exenatide) and thiazolidinediones (TZDs or glitazones) as second-tier agents for management of blood glucose levels. The amylin agonists, alpha-glucosidase inhibitors, glinides and DPP-4 inhibitors were not included in their two tiers of preferred agents, though they may be appropriate choices in selected patients. Partially in response to this Consensus Statement, the American Association of Clinical Endocrinologists and the American College of Endocrinology convened a consensus panel and issued their statement on glycemic control in Type 2 diabetes. In developing their treatment algorithm, they set as priorities minimizing the risk and severity of hypoglycemia and minimizing the risk and magnitude of weight gain. Consequently, the AACE/ACE Diabetes algorithm for glycemic control features a more prominent role for the DPP-4 inhibitors and amylin agonists due to impact on weight (DPP-4 – weight neutral; amylin agonists – weight loss) and their lack of hypoglycemia.
Learning Objectives:
Following completion of this program, participants will be able to:
Describe the similarities and differences between the two current treatment algorithms for the management of blood glucose levels in Type 2 diabetes
Identify the medications that have a positive or negative impact on weight in each of the treatment algorithms
Identify the medications that may cause hypoglycemia in each of the treatment algorithms
Recognize the appropriate therapeutic choices in individual patients based on their demographic and clinical characteristics
Agenda
Disclosures and Introduction (2 minutes)
The similarities and differences between the two current treatment algorithms for the management of blood glucose levels in Type 2 diabetes (10 minutes)
The medications that have a positive or negative impact on weight in each of the treatment algorithms (15 minutes)
Medications that may cause hypoglycemia in each of the treatment algorithms (15 minutes)
The appropriate therapeutic choices in individual patients based on their demographic and clinical characteristics (15 minutes)
References, Summary and Conclusions (3 min)